Rosana Hernandez
Medical · South Gate, CANPI 1972849693
Payments from drug & device makers
Across 188 payments — averaging $20.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$801
- AstraZeneca$407
- Boehringer Ingelheim$330
- Lilly USA, LLC$272
- Johnson & Johnson$269
- AbbVie$263
- plus $2K from 19 others
What the payments were for
- Food & beverage$3,911100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $801 |
| AstraZeneca | 14 | $407 |
| Boehringer Ingelheim | 12 | $330 |
| Lilly USA, LLC | 12 | $272 |
| Johnson & Johnson | 10 | $269 |
| AbbVie | 12 | $263 |
| Sanofi-aventis U.S. LLC | 11 | $212 |
| GSK | 10 | $192 |
| Dexcom, Inc. | 9 | $183 |
| Pfizer | 8 | $180 |
| Bayer | 8 | $179 |
| Merck | 6 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $74 |
| Exact Sciences | 3 | $73 |
| Amarin Pharma, Inc. | 3 | $72 |
| Amgen | 3 | $63 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Madrigal Pharmaceuticals | 1 | $35 |
| Sanofi Pasteur Inc. | 2 | $33 |
| Sage Therapeutics, LLC | 1 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Seqirus USA Inc | 1 | $25 |
| Evofem Biosciences, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $15 |
How this compares
$3,911 in reported general payments places this provider in the 80th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $82,939 |
| JardianceEmpagliflozin | 24 | $29,796 |
| FarxigaDapagliflozin Propanediol | 15 | $19,747 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $16,035 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $13,481 |
| TrulicityDulaglutide | 11 | $10,243 |
| VascepaIcosapent Ethyl | 25 | $9,945 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $6,603 |
| Atorvastatin Calcium | 162 | $1,714 |
| Omega-3 Acid Ethyl Esters | 30 | $1,552 |
| Losartan Potassium | 81 | $1,010 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $869 |
| Olmesartan Medoxomil | 29 | $735 |
| Amlodipine Besylate | 86 | $657 |
| Levothyroxine Sodium | 47 | $580 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $801 | $82,93983 claims |
| Boehringer IngelheimJardiance | $330 | $29,79624 claims |
| AstraZenecaFarxiga | $407 | $19,74715 claims |
| MerckJanumet | $100 | $13,48112 claims |
| Lilly USA, LLCTrulicity | $272 | $10,24311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 medical providers in California.
Other medical in South Gate
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- Deirdre MoxleyFullerton$149K
- Tri leGardena$127K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.